1887

Abstract

A 12 month survey of candidaemia in Scotland, UK, in which every Scottish hospital laboratory submitted all blood isolates of yeasts for identification, strain typing and susceptibility testing, provided 300 isolates from 242 patients, generating incidence data of 4.8 cases per 100 000 population per year and 5.9 cases per 100 000 acute occupied bed days; 27.9 % of cases occurred in intensive care units. More than half the patients with candidaemia had an underlying disease involving the abdomen, 78 % had an indwelling intravenous catheter, 62 % had suffered a bacterial infection within the 2 weeks prior to candidaemia and 37 % had undergone a laparotomy. was the infecting species in 50 % of cases, followed by (21 %) and (12 %). Seven cases of candidaemia were caused by , which was more prevalent even than and (six cases each). Among isolates, 55 % showed reduced susceptibility to fluconazole, but azole resistance among other species was extremely low. Multilocus sequence typing showed isolates with high similarity came from different hospitals across the country, and many different types came from the hospitals that submitted the most isolates, indicating no tendency towards hospital-specific endemic strains. Multiple isolates of and from individual patients were of the same strain type with single exceptions for each species. The high prevalence of candidaemia in Scotland, relative to other population-based European studies, and the high level of reduced fluconazole susceptibility of Scottish isolates warrant continued future surveillance of invasive infections.

Loading

Article metrics loading...

/content/journal/jmm/10.1099/jmm.0.47239-0
2007-08-01
2019-10-21
Loading full text...

Full text loading...

/deliver/fulltext/jmm/56/8/1066.html?itemId=/content/journal/jmm/10.1099/jmm.0.47239-0&mimeType=html&fmt=ahah

References

  1. Almirante, B., Rodriguez, D., Park, B. J., Cuenca-Estrella, M., Planes, A. M., Almela, M., Mensa, J., Sanchez, F., Ayats, J. & other authors ( 2005; ). Epidemiology and predictors of mortality in cases of Candida bloodstream infection: results from population-based surveillance, Barcelona, Spain, from 2002 to 2003. J Clin Microbiol 43, 1829–1835.[CrossRef]
    [Google Scholar]
  2. Andes, D. ( 2004; ). Antifungal pharmacokinetics and pharmacodynamics: understanding the implications for antifungal drug resistance. Drug Resist Updat 7, 185–194.[CrossRef]
    [Google Scholar]
  3. Andes, D. & van Ogtrop, H. ( 1999; ). Characterization and quantitation of the pharmacodynamics of fluconazole in a neutropenic murine disseminated candidiasis infection model. Antimicrob Agents Chemother 43, 2116–2120.
    [Google Scholar]
  4. HPA ( 2004; ). Candidaemia reports, England, Wales, and Northern Ireland: 2003. CDR Weekly 14, 1–3 http://www.hpa.org.uk/cdr/archives/2004/cdr4304.pdf
    [Google Scholar]
  5. Arendrup, M. C., Fuursted, K., Gahrn-Hansen, B., Jensen, I. M., Knudsen, J. D., Lundgren, B., Schonheyder, H. C. & Tvede, M. ( 2005; ). Seminational surveillance of fungemia in Denmark: notably high rates of fungemia and numbers of isolates with reduced azole susceptibility. J Clin Microbiol 43, 4434–4440.[CrossRef]
    [Google Scholar]
  6. Arthington-Skaggs, B. A., Lee-Yang, W., Ciblak, M. A., Frade, J. P., Brandt, M. E., Hajjeh, R. A., Harrison, L. H., Sofair, A. N. & Warnock, D. W. ( 2002; ). Comparison of visual and spectrophotometric methods of broth microdilution MIC end point determination and evaluation of a sterol quantitation method for in vitro susceptibility testing of fluconazole and itraconazole against trailing and nontrailing Candida isolates. Antimicrob Agents Chemother 46, 2477–2481.[CrossRef]
    [Google Scholar]
  7. Asmundsdottir, L. R., Erlendsdottir, H. & Gottfredsson, M. ( 2002; ). Increasing incidence of candidemia: results from a 20-year nationwide study in Iceland. J Clin Microbiol 40, 3489–3492.[CrossRef]
    [Google Scholar]
  8. Bassetti, M., Righi, E., Costa, A., Fasce, R., Molinari, M. P., Rosso, R., Pallavicini, F. B. & Viscoli, C. ( 2006; ). Epidemiological trends in nosocomial candidemia in intensive care. BMC Infect Dis 6, 21 [CrossRef]
    [Google Scholar]
  9. Blignaut, E., Pujol, C., Lockhart, S., Joly, S. & Soll, D. R. ( 2002; ). Ca3 fingerprinting of Candida albicans isolates from human immunodeficiency virus-positive and healthy individuals reveals a new clade in South Africa. J Clin Microbiol 40, 826–836.[CrossRef]
    [Google Scholar]
  10. Blijlevens, N. M. A., Donnelly, J. P. & de Pauw, B. E. ( 2002; ). Impaired gut function as risk factor for invasive candidiasis in neutropenic patients. Br J Haematol 117, 259–264.[CrossRef]
    [Google Scholar]
  11. Blumberg, H. M., Jarvis, W. R., Soucie, J. M., Edwards, J. E., Patterson, J. E., Pfaller, M. A., Rangel-Frausto, M. S., Rinaldi, M. G., Saiman, L. & other authors ( 2001; ). Risk factors for candidal bloodstream infections in surgical intensive care unit patients: the NEMIS prospective multicenter study. Clin Infect Dis 33, 177–186.[CrossRef]
    [Google Scholar]
  12. Bougnoux, M. E., Tavanti, A., Bouchier, C., Gow, N. A. R., Magnier, A., Davidson, A. D., Maiden, M. C. J., d'Enfert, C. & Odds, F. C. ( 2003; ). Collaborative consensus for optimized multilocus sequence typing of Candida albicans. J Clin Microbiol 41, 5265–5266.[CrossRef]
    [Google Scholar]
  13. Chan-Tack, K. M. ( 2005; ). Fatal Candida dubliniensis septicemia in a patient with AIDS. Clin Infect Dis 40, 1209–1210.[CrossRef]
    [Google Scholar]
  14. Cohen, R., Roth, F. J., Delgado, E., Ahearn, D. G. & Kalser, M. H. ( 1969; ). Fungal flora of the normal human small and large intestine. N Engl J Med 280, 638–641.[CrossRef]
    [Google Scholar]
  15. Cuenca-Estrella, M., Rodero, L., Garcia-Effron, G. & Rodriguez-Tudela, J. L. ( 2002a; ). Antifungal susceptibilities of Candida spp. isolated from blood in Spain and Argentina, 1996–1999. J Antimicrob Chemother 49, 981–987.[CrossRef]
    [Google Scholar]
  16. Cuenca-Estrella, M., Lee-Yang, W., Ciblak, M. A., Arthington-Skaggs, B. A., Mellado, E., Warnock, D. W. & Rodriguez-Tudela, J. L. ( 2002b; ). Comparative evaluation of NCCLS M27-A and EUCAST broth microdilution procedures for antifungal susceptibility testing of Candida species. Antimicrob Agents Chemother 46, 3644–3647.[CrossRef]
    [Google Scholar]
  17. Cuenca-Estrella, M., Moore, C. B., Barchiesi, F., Bille, J., Chryssanthou, E., Denning, D. W., Donnelly, J. P., Dromer, F., Dupont, B. & other authors ( 2003; ). Multicenter evaluation of the reproducibility of the proposed antifungal susceptibility testing method for fermentative yeasts of the Antifungal Susceptibility Testing Subcommittee of the European Committee on Antimicrobial Susceptibility Testing (AFST-EUCAST). Clin Microbiol Infect 9, 467–474.[CrossRef]
    [Google Scholar]
  18. Cuenca-Estrella, M., Gomez-Lopez, A., Mellado, E. & Rodriguez-Tudela, J. L. ( 2005; ). Correlation between the procedure for antifungal susceptibility testing for Candida spp. of the European Committee on Antibiotic Susceptibility Testing (EUCAST) and four commercial techniques. Clin Microbiol Infect 11, 486–492.[CrossRef]
    [Google Scholar]
  19. Diekema, D. J., Messer, S. A., Brueggemann, A. B., Coffman, S. L., Doern, G. V., Herwaldt, L. A. & Pfaller, M. A. ( 2002; ). Epidemiology of candidemia: 3-year results from the emerging infections and the epidemiology of Iowa organisms study. J Clin Microbiol 40, 1298–1302.[CrossRef]
    [Google Scholar]
  20. Dodgson, A. R., Pujol, C., Denning, D. W., Soll, D. R. & Fox, A. J. ( 2003; ). Multilocus sequence typing of Candida glabrata reveals geographically enriched clades. J Clin Microbiol 41, 5709–5717.[CrossRef]
    [Google Scholar]
  21. Feil, E. J., Li, B. C., Aanensen, D. M., Hanage, W. P. & Spratt, B. G. ( 2004; ). eBURST: inferring patterns of evolutionary descent among clusters of related bacterial genotypes from multilocus sequence typing data. J Bacteriol 186, 1518–1530.[CrossRef]
    [Google Scholar]
  22. Fotedar, R. & Al Hedaithy, S. S. A. ( 2003; ). Candida dubliniensis at a university hospital in Saudi Arabia. J Clin Microbiol 41, 1907–1911.[CrossRef]
    [Google Scholar]
  23. Hajjeh, R. A., Sofair, A. N., Harrison, L. H., Lyon, G. M., Arthington-Skaggs, B. A., Mirza, S. A., Phelan, M., Morgan, J., Lee-Yang, W. & other authors ( 2004; ). Incidence of bloodstream infections due to Candida species and in vitro susceptibilities of isolates collected from 1998 to 2000 in a population-based active surveillance program. J Clin Microbiol 42, 1519–1527.[CrossRef]
    [Google Scholar]
  24. Kao, A. S., Brandt, M. E., Pruitt, W. R., Conn, L. A., Perkins, B. A., Stephens, D. S., Baughman, W. S., Reingold, A. L., Rothrock, G. A. & other authors ( 1999; ). The epidemiology of candidemia in two United States cities: results of a population-based active surveillance. Clin Infect Dis 29, 1164–1170.[CrossRef]
    [Google Scholar]
  25. Kibbler, C. C., Seaton, S., Barnes, R. A., Gransden, W. R., Holliman, R. E., Johnson, E. M., Perry, J. D., Sullivan, D. J. & Wilson, J. A. ( 2003; ). Management and outcome of bloodstream infections due to Candida species in England and Wales. J Hosp Infect 54, 18–24.[CrossRef]
    [Google Scholar]
  26. Laupland, K. B., Gregson, D. B., Church, D. L., Ross, T. & Elsayed, S. ( 2005; ). Invasive Candida species infections: a 5 year population-based assessment. J Antimicrob Chemother 56, 532–537.[CrossRef]
    [Google Scholar]
  27. Levy, I., Rubin, L. G., Vasishtha, S., Tucci, V. & Sood, S. K. ( 1998; ). Emergence of Candida parapsilosis as the predominant species causing candidemia in children. Clin Infect Dis 26, 1086–1088.[CrossRef]
    [Google Scholar]
  28. Marchetti, O., Bille, J., Fluckiger, U., Eggimann, P., Ruef, C., Garbino, J., Calandra, T., Glauser, M. P., Tauber, M. G. & Pittet, D. ( 2004; ). Epidemiology of candidemia in Swiss tertiary care hospitals: secular trends, 1991–2000. Clin Infect Dis 38, 311–320.[CrossRef]
    [Google Scholar]
  29. Marco, F., Danes, C., Almela, M., Jurado, A., Mensa, J., de la Bellacasa, J. P., Espasa, M., Martinez, J. A. & de Anta, M. T. J. ( 2003; ). Trends in frequency and in vitro susceptibilities to antifungal agents, including voriconazole and anidulafungin, of Candida bloodstream isolates. Results from a six-year study (1996–2001). Diagn Microbiol Infect Dis 46, 259–264.[CrossRef]
    [Google Scholar]
  30. McCullough, M. J., Clemons, K. V. & Stevens, D. A. ( 1999; ). Molecular and phenotypic characterization of genotypic Candida albicans subgroups and comparison with Candida dubliniensis and Candida stellatoidea. J Clin Microbiol 37, 417–421.
    [Google Scholar]
  31. McNeil, M. M., Nash, S. L., Hajjeh, R. A., Phelan, M. A., Conn, L. A., Plikaytis, B. D. & Warnock, D. W. ( 2001; ). Trends in mortality due to invasive mycotic diseases in the United States, 1980–1997. Clin Infect Dis 33, 641–647.[CrossRef]
    [Google Scholar]
  32. Meis, J. F. G. M., Ruhnke, M., de Pauw, B. E., Odds, F. C., Siegert, W. & Verweij, P. E. ( 1999; ). Candida dubliniensis candidemia in patients with chemotherapy-induced neutropenia and bone marrow transplantation. Emerg Infect Dis 5, 150–153.[CrossRef]
    [Google Scholar]
  33. Morgan, J. ( 2005; ). Global trends in candidemia: review of reports from 1995–2005. Curr Infect Dis Rep 7, 429–439.[CrossRef]
    [Google Scholar]
  34. NCCLS ( 2002; ). Reference Method for Broth Dilution Antifungal Susceptibility Testing of Yeasts, approved standard, 2nd edn. Wayne, PA: National Commmittee for Clinical Laboratory Standards.
  35. Odds, F. C. ( 1988; ). Candida and Candidosis, 2nd edn. London: Bailliere Tindall.
  36. Odds, F. C. & Bernaerts, R. ( 1994; ). CHROMagar Candida, a new differential isolation medium for presumptive identification of clinically important Candida species. J Clin Microbiol 32, 1923–1929.
    [Google Scholar]
  37. Odds, F. C., Vranckx, L. & Woestenborghs, F. ( 1995; ). Antifungal susceptibility testing of yeasts: evaluation of technical variables for test automation. Antimicrob Agents Chemother 39, 2051–2060.[CrossRef]
    [Google Scholar]
  38. Odds, F. C., Davidson, A. D., Jacobsen, M. D., Tavanti, A., Whyte, J. A., Kibbler, C. C., Ellis, D. H., Maiden, M. C. J., Shaw, D. J. & Gow, N. A. R. ( 2006; ). Candida albicans strain maintenance, replacement and micro-variation demonstrated by multilocus sequence typing. J Clin Microbiol 44, 3647–3658.[CrossRef]
    [Google Scholar]
  39. Odds, F. C., Bougnoux, M.-E., Shaw, D. J., Bain, J. M., Davidson, A. D., Diogo, D., Jacobsen, M. D., Lecomte, M., Li, S.-Y. & other authors ( 2007; ). Molecular phylogenetics of Candida albicans. Eukaryot Cell 6, 1041–1052.[CrossRef]
    [Google Scholar]
  40. Pappas, P. G., Rex, J. H., Sobel, J. D., Filler, S. G., Dismukes, W. E., Walsh, T. J. & Edwards, J. E. ( 2004; ). Guidelines for treatment of candidiasis. Clin Infect Dis 38, 161–189.[CrossRef]
    [Google Scholar]
  41. Pemán, J., Canton, E. & Gobernado, M. ( 2005; ). Epidemiology and antifungal susceptibility of Candida species isolated from blood: results of a 2-year multicentre study in Spain. Eur J Clin Microbiol Infect Dis 24, 23–30.[CrossRef]
    [Google Scholar]
  42. Pfaller, M. A., Diekema, D. J., Jones, R. N., Messer, S. A. & Hollis, R. J. ( 2002; ). Trends in antifungal susceptibility of Candida spp. isolated from pediatric and adult patients with bloodstream infections: SENTRY Antimicrobial Surveillance Program, 1997 to 2000. J Clin Microbiol 40, 852–856.[CrossRef]
    [Google Scholar]
  43. Pfaller, M. A., Diekema, D. J. & Sheehan, D. J. ( 2006; ). Interpretive breakpoints for fluconazole and Candida revisited: a blueprint for the future of antifungal susceptibility testing. Clin Microbiol Rev 19, 435–447.[CrossRef]
    [Google Scholar]
  44. Poikonen, E., Lyytikainen, O., Anttila, V. J. & Ruutu, P. ( 2003; ). Candidemia in Finland, 1995–1999. Emerg Infect Dis 9, 985–990.[CrossRef]
    [Google Scholar]
  45. Price, M. F., Larocco, M. T. & Gentry, L. O. ( 1994; ). Fluconazole susceptibilities of Candida species and distribution of species recovered from blood cultures over a 5-year period. Antimicrob Agents Chemother 38, 1422–1424.[CrossRef]
    [Google Scholar]
  46. Pujol, C., Pfaller, M. & Soll, D. R. ( 2002; ). Ca3 fingerprinting of Candida albicans bloodstream isolates from the United States, Canada, South America, and Europe reveals a European clade. J Clin Microbiol 40, 2729–2740.[CrossRef]
    [Google Scholar]
  47. Rangel-Frausto, M. S., Wiblin, T., Blumberg, H. M., Saiman, L., Patterson, J., Rinaldi, M., Pfaller, M., Edwards, J. E., Jarvis, W. & other authors ( 1999; ). National Epidemiology of Mycoses Survey (NEMIS): variations in rates of bloodstream infections due to Candida species in seven surgical intensive care units and six neonatal intensive care units. Clin Infect Dis 29, 253–258.[CrossRef]
    [Google Scholar]
  48. Rex, J. H., Nelson, P. W., Paetznick, V. L., Lozanochiu, M., Espinelingroff, A. & Anaissie, E. J. ( 1998; ). Optimizing the correlation between results of testing in vitro and therapeutic outcome in vivo for fluconazole by testing critical isolates in a murine model of invasive candidiasis. Antimicrob Agents Chemother 42, 129–134.
    [Google Scholar]
  49. San Miguel, L. G., Cobo, J., Otheo, E., Sanchez-Sousa, A., Abraira, V. & Moreno, S. ( 2005; ). Secular trends of candidemia in a large tertiary-care hospital from 1988 to 2000: emergence of Candida parapsilosis. Infect Control Hosp Epidemiol 26, 548–552.[CrossRef]
    [Google Scholar]
  50. Sandven, P. ( 2000; ). Epidemiology of candidemia. Rev Iberoam Micol 17, 73–81.
    [Google Scholar]
  51. Sandven, P., Bevanger, L., Digranes, A., Haukland, H. H., Mannsaker, T. & Gaustad, P. ( 2006; ). Candidemia in Norway (1991 to 2003): results from a nationwide study. J Clin Microbiol 44, 1977–1981.[CrossRef]
    [Google Scholar]
  52. Soll, D. R. & Pujol, C. ( 2003; ). Candida albicans clades. FEMS Immunol Med Microbiol 39, 1–7.[CrossRef]
    [Google Scholar]
  53. Stone, H. H., Kold, L. D., Currie, C. A., Geheber, C. E. & Cuzzell, J. Z. ( 1974; ). Candida sepsis: pathogenesis and principles of treatment. Ann Surg 179, 697–711.[CrossRef]
    [Google Scholar]
  54. Tavanti, A., Davidson, A. D., Gow, N. A. R., Maiden, M. C. J. & Odds, F. C. ( 2005a; ). Candida orthopsilosis and Candida metapsilosis spp. nov to replace Candida parapsilosis groups II and III. J Clin Microbiol 43, 284–292.[CrossRef]
    [Google Scholar]
  55. Tavanti, A., Davidson, A. D., Fordyce, M. J., Gow, N. A. R., Maiden, M. C. J. & Odds, F. C. ( 2005b; ). Population structure and properties of Candida albicans, as determined by multilocus sequence typing. J Clin Microbiol 43, 5601–5613.[CrossRef]
    [Google Scholar]
  56. Tavanti, A., Davidson, A. D., Johnson, E. M., Maiden, M. C. J., Shaw, D. J., Gow, N. A. R. & Odds, F. C. ( 2005c; ). Multilocus sequence typing for differentiation of strains of Candida tropicalis. J Clin Microbiol 43, 5593–5600.[CrossRef]
    [Google Scholar]
  57. Tortorano, A. M., Peman, J., Bernhardt, H., Klingspor, L., Kibbler, C. C., Faure, O., Biraghi, E., Canton, E., Zimmermann, K. & other authors ( 2004; ). Epidemiology of candidaemia in Europe: results of 28-month European Confederation of Medical Mycology (ECMM) hospital-based surveillance study. Eur J Clin Microbiol Infect Dis 23, 317–322.[CrossRef]
    [Google Scholar]
  58. Trick, W. E., Fridkin, S. K., Edwards, J. R., Hajjeh, R. A. & Gaynes, R. P. ( 2002; ). Secular trend of hospital-acquired candidemia among intensive care unit patients in the United States during 1989–1999. Clin Infect Dis 35, 627–630.[CrossRef]
    [Google Scholar]
  59. Vazquez, J. A. & Sobel, J. D. ( 2003; ). Candidiasis. In Clinical Mycology, pp. 143–187. Edited by W. E. Dismukes, P. G. Pappas & J. D. Sobel. Oxford: Oxford University Press.
http://instance.metastore.ingenta.com/content/journal/jmm/10.1099/jmm.0.47239-0
Loading
/content/journal/jmm/10.1099/jmm.0.47239-0
Loading

Data & Media loading...

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error